NeoGenomics stock gained 3.88 percent after Q2 earnings beat
NeoGenomics stock rose 3.88 percent on October 2, 2026, closing at USD 18.47 on Nasdaq, following a strong Q2 earnings report. The company beat revenue expectations with USD 201.66 million and raised its full-year revenue guidance to USD 802 million-USD 806 million. Analysts remain divided on the stock, with a consensus of Moderate Buy and an average price target of USD 17.67.
Precision Trading with Neogenomics Inc. (NEO) Risk Zones
This article provides a detailed analysis of Neogenomics Inc. (NEO) using AI models to identify trading risk zones and strategies. It highlights weak near-term sentiment challenging long-term strength and presents specific institutional trading strategies including long, breakout, and short setups with entry points, targets, and stop losses. The analysis also covers multi-timeframe signal strengths, support, and resistance levels for precision trading.
NeoGenomics, Inc. - Common Stock (Nasdaq:NEO) Stock Quote
This article provides a stock quote and recent news for NeoGenomics, Inc. (Nasdaq: NEO). It details the company's stock performance, including a 103.0% return over the past year and a 138% increase in the last six months. The article also lists recent headlines, financial data, and frequently asked questions about the company's public trading status and market information.
NeoGenomics, Inc. (NEO) Stock Price, News, Quote & History
This page provides a comprehensive overview of NeoGenomics, Inc. (NEO) stock, including its current price, market data, historical performance, and key financial metrics. It details the company's operations as a cancer-focused testing laboratory, offering various diagnostic services and insights into its earnings, analyst recommendations, and valuation measures.
Zacks Research Downgrades NeoGenomics (NASDAQ:NEO) to Hold
Zacks Research has downgraded NeoGenomics (NASDAQ:NEO) from a "strong buy" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $17.67. This comes as NeoGenomics reported stronger-than-expected quarterly earnings of $0.05 EPS and revenue of $201.66 million, surpassing analyst estimates. Institutional investors hold a significant portion of the stock, with First Light Asset Management increasing its stake by 26.2% in the second quarter.
NeoGenomics stock trades at EUR 17.04 after Q2 EPS beat
NeoGenomics stock is trading at EUR 17.04 after reporting strong Q2 earnings, with revenue up 11.20% year over year to USD 201.66 million and EPS of USD 0.05, surpassing the USD 0.03 consensus. The company highlighted next-generation sequencing and minimal residual disease testing as key growth drivers, with NGS revenue growing 26% in the first half of 2026. Analysts maintain a "Moderate Buy" consensus with an average 12-month target of USD 17.67.
NeoGenomics, Inc. (NEO) Stock forecasts
Argus has issued a report on NeoGenomics, Inc. (NEO), an oncology diagnostic testing and consultative services provider. The report was published on September 23, 2026. The current price of NEO stock is $19.56.
NeoGenomics stock falls 2.81 percent after Q2 revenue beat
NeoGenomics stock dropped 2.81% to USD 18.36 on September 23, 2026, despite reporting a second-quarter revenue beat. The company's Q2 revenue rose 11.2% to USD 201.66 million, surpassing expectations. Investors are assessing the company's precision oncology strategy and whether increased testing volumes will translate into sustained profitability.
Precision Oncology Expansion Could Be A Game Changer For NeoGenomics Stock
NeoGenomics (NasdaqCM:NEO) is focusing on expanding its community-based precision oncology business, specifically in next-generation sequencing (NGS) and minimal residual disease (MRD) testing. This strategy aims to leverage higher-value tests to absorb fixed lab costs, as NGS already contributes a significant portion of clinical revenue despite making up a smaller volume of tests. While competitive pressures and ongoing losses remain, the company projects substantial revenue and earnings growth by 2029 through this shift towards complex diagnostics.
Neogenomics stock hits 52-week high at 19.78 USD
NeoGenomics Inc. stock has reached a new 52-week high of $19.78 USD, marking a significant 128.77% increase over the past year. Despite its strong performance and raised full-year guidance, InvestingPro's Fair Value analysis suggests the stock might be overvalued. Analysts predict the company will be profitable this year, with upward revisions to earnings estimates.
Squarepoint Ops LLC Purchases 120,342 Shares of NeoGenomics, Inc. $NEO
Squarepoint Ops LLC increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 118.3% during the second quarter, acquiring an additional 120,342 shares to own a total of 222,036 shares valued at $3.24 million. Institutional investors and hedge funds now collectively own 98.5% of NeoGenomics' stock. The company has a "Moderate Buy" consensus rating from analysts, with several firms recently upgrading the stock or raising price targets, following NeoGenomics exceeding its quarterly earnings and revenue expectations.
WINTON GROUP Ltd Purchases New Position in NeoGenomics, Inc. $NEO
WINTON GROUP Ltd has acquired a new stake of 63,379 shares in NeoGenomics, Inc. (NASDAQ:NEO) during the second quarter, valued at approximately $925,000. This comes as institutional investors now collectively own 98.5% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $17.67. NeoGenomics also surpassed quarterly earnings expectations, reporting $0.05 EPS against a $0.03 consensus and revenue of $201.66 million, an 11.2% increase year-over-year.
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Representative Gilbert Ray Cisneros, Jr. recently purchased between $1,001 and $15,000 worth of NeoGenomics, Inc. (NASDAQ:NEO) shares on August 7th, as disclosed in a September 10th filing. This transaction occurred amidst NeoGenomics reporting strong quarterly earnings, beating analyst estimates, although the company still faces a negative net margin and projected full-year loss. The stock currently holds a "Moderate Buy" consensus rating from analysts, with institutional investors owning a significant majority of its shares.
A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
This article reviews the Q2 earnings for several testing and diagnostics services stocks, highlighting NeoGenomics' strong performance which saw its stock rise significantly after beating analyst expectations. It also discusses RadNet's exceptional quarter, Labcorp's weaker performance, and strong results from Quest Diagnostics and Guardant Health. The article also briefly touches upon market uncertainties, including the impact of AI and geopolitical events.
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Moderate Buy" by Analysts
NeoGenomics, Inc. (NASDAQ:NEO) has received a consensus "Moderate Buy" rating from ten analysts, with an average 12-month price target of $17.67. The company recently surpassed earnings expectations, reporting $0.05 EPS against a $0.03 consensus and revenue of $201.66 million, an 11.2% increase year-over-year. Institutional investors hold a significant 98.5% of outstanding shares, and the stock opened at $17.61 with a market capitalization of $2.26 billion.
NeoGenomics, Inc. $NEO Shares Bought by First Light Asset Management LLC
First Light Asset Management LLC significantly increased its stake in NeoGenomics, Inc. (NEO) by 26.2% during the second quarter, making it their largest portfolio position. This move is part of a broader trend of high institutional ownership in NeoGenomics, which recently surpassed its quarterly earnings and revenue expectations. Analysts maintain a "Moderate Buy" rating with a positive price target, reflecting confidence in the medical research company's performance.
NeoGenomics EVP Alicia Olivo Surrenders Shares for Tax Withholding Following Restricted Stock Vesting
Alicia C. Olivo, EVP at NeoGenomics Inc., surrendered 2,692 common stock shares on September 1, 2026, for tax withholding purposes related to restricted stock vesting. This transaction, coded "F," means the shares were withheld to cover tax liabilities rather than being sold in the open market. Post-transaction, Olivo directly holds 90,875 shares and has extensive derivative holdings, including stock options and restricted/performance stock units.
Bank of New York Mellon Corp Takes Position in NeoGenomics, Inc. $NEO
Bank of New York Mellon Corp has acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO), purchasing 736,368 shares valued at approximately $10.7 million. This acquisition, along with other institutional investments, means that institutional investors and hedge funds collectively own 98.5% of NeoGenomics. The company recently reported strong quarterly earnings, beating estimates with $0.05 per share and an 11.2% year-over-year revenue increase, and analysts maintain a "Moderate Buy" rating with an average price target of $17.67.
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14–16, 2026. Management's fireside chat will be held on September 15th at 7:45 am ET, with a live audio webcast and archived replay available online. NeoGenomics specializes in oncology diagnostic solutions and cancer genetics testing.
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics has announced that its RaDaR ST molecular residual disease (MRD) assay has received expanded Medicare coverage for monitoring immunotherapy response in patients with late-stage solid tumors. This is the third Medicare-covered indication for RaDaR ST, which aims to provide clinicians with dynamic tools to evaluate patient response to immunotherapy over time, complementing traditional assessment methods. The company expects further reimbursement decisions to support growth and broader clinical adoption of RaDaR ST in the coming years.
NeoGenomics (NEO) COO converts 28K stock units into common shares
NeoGenomics (NEO) COO Warren Stone exercised 28,106 Restricted Stock Units (RSUs) into common shares on August 21, 2026, with 11,060 shares subsequently delivered or withheld for tax liabilities. This transaction is detailed in a recent Form 4 SEC filing, which also outlines Stone's remaining equity incentives, including various tranches of stock options, RSUs, and performance stock units. The filing provides comprehensive footnotes explaining the vesting schedules and performance criteria for these equity awards.
Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST
NeoGenomics recently secured a significant court victory against Natera, invalidating key patents and reducing legal hurdles for its RaDaR ST assay. This ruling is expected to enhance RaDaR ST's competitive position in molecular residual disease testing and strengthen NeoGenomics' oncology test menu. Despite current losses, the company aims for consistent earnings growth through its expanded offerings, including the PanTracer liquid biopsy and PanTracer Pro portfolio.
Neogenomics stock hits 52-week high at 16.93 USD By Investing.com
NeoGenomics Inc. stock has reached a new 52-week high of $16.93, with shares currently trading at $16.98, reflecting a 1-year change of 154.81% and an actual 1-year return of 167.48%. Despite being deemed overvalued by InvestingPro analysis, the company reported strong Q2 2026 earnings, surpassing Wall Street expectations, leading Needham to raise its price target to $19.00. The company also announced the upcoming departure of its Executive Vice President and General Counsel, Alicia Olivo.
NeoGenomics Inc (NEO) Stock Price, Quote, News & History
This page provides comprehensive information on NeoGenomics Inc (NEO) stock, including its current price, key statistics, recent news, financial data, and analyst forecasts. As of August 21, 2026, NEO closed at $16.98, with after-hours trading at $17.07, and has recently seen news about a court win regarding Natera patents. The company operates in the Health Care Providers & Services industry, offering oncology diagnostic testing.
Neogenomics stock hits 52-week high at 16.93 USD
NeoGenomics Inc. (NEO) stock has reached a new 52-week high of $16.93, currently trading at $16.98, reflecting a robust 1-year change of 154.81% and an actual 1-year return of 167.48%. Despite being considered overvalued by InvestingPro, the company recently surpassed Q2 2026 earnings expectations and raised its full-year guidance, leading Needham to increase its price target to $19.00. The stock, however, carries a high beta of 1.73, indicating significant volatility.
NeoGenomics, Inc. Revenue Breakdown – NASDAQ:NEO
NeoGenomics, Inc. (NASDAQ: NEO) generated $727.33 million in revenue last year, with its top-performing segment, Client Direct Billing, contributing $518.84 million. The majority of the company's revenue, $727.33 million, originated from the United States. This indicates a strong domestic market presence and reliance on direct client billing for a significant portion of its income.
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of "Moderate Buy" by Analysts
NeoGenomics, Inc. (NASDAQ:NEO) has received an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $16.71, slightly above its recent opening price of $15.94. The company surpassed quarterly earnings and revenue expectations, reporting $0.05 EPS and $201.66 million in revenue, an 11.2% year-over-year increase. Institutional investors hold a significant 98.5% of outstanding shares, while a director recently sold a portion of their holdings under a pre-arranged trading plan.
NeoGenomics | SCHEDULE 13G/A: Others
This article consists solely of the title "NeoGenomics | SCHEDULE 13G/A: Others" and the content "Document". It indicates the filing of a Schedule 13G/A for NeoGenomics, likely pertaining to an amendment by other reporting persons.
NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens
Mathew P. Arens and First Light Asset Management, LLC have reported their beneficial ownership in NeoGenomics, Inc. through a Schedule 13G/A filing. Arens beneficially owns 8.37% of NeoGenomics' common stock, totaling 10,759,586 shares, which includes holdings through First Light, direct shares, and a joint account. First Light Asset Management independently holds a 7.99% stake, representing 10,260,186 shares.
California State Teachers Retirement System Raises Position in NeoGenomics, Inc. $NEO
The California State Teachers Retirement System significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 56.8% in the first quarter, now owning 194,103 shares valued at $1.44 million. This move is reflective of a broader positive sentiment from institutional investors, who collectively own 98.5% of the company. Analysts maintain a "Moderate Buy" rating with an average target price of $16.71, and NeoGenomics recently surpassed earnings and revenue estimates.
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan recently sold US$321k worth of company shares, representing an 80% reduction in his position. This significant insider selling, combined with no insider purchases over the last year, raises concerns about the company's valuation and signals caution for potential investors. Insiders currently own 2.1% of NeoGenomics shares, totaling approximately US$45 million.
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding
NeoGenomics' Senior VP & Chief Accounting Officer, Gregory Aunan, recently sold US$321k worth of shares, representing an 80% reduction in his holdings at an average price of US$16.07. This significant insider selling event, occurring slightly below the current share price of US$16.53, raises caution among investors despite insiders owning 2.1% of the company's shares. No insider purchases have been made over the last year, suggesting a cautious outlook for the company.
NeoGenomics announces planned departure of General Counsel Alicia Olivo
NeoGenomics, Inc. announced the planned departure of Alicia Olivo, Executive Vice President, General Counsel, and Business Development, effective September 21, 2026. Ms. Olivo will remain with the company until October 2, 2026, for a smooth transition and will receive separation payments as per her employment agreement. This announcement follows NeoGenomics reporting strong Q2 2026 earnings and revenue, surpassing Wall Street expectations, which led Needham to raise its price target for the company.
Renaissance Technologies LLC Acquires New Shares in NeoGenomics, Inc. $NEO
Renaissance Technologies LLC has acquired 254,172 shares of NeoGenomics, Inc. (NASDAQ:NEO) worth approximately $1.89 million, increasing institutional ownership of the company to 98.5%. This comes as NeoGenomics exceeded Q1 earnings expectations with $0.05 EPS and $201.66 million in revenue, an 11.2% year-over-year increase. Analysts maintain a "Moderate Buy" rating for NEO with an average price target of $16.71.
Technical Reactions to NEO Trends in Macro Strategies
This article provides a technical analysis of Neogenomics Inc. (NYSE: NEO) based on AI models, indicating strong sentiment across all time horizons and compelling upside potential. It outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, along with a multi-timeframe signal analysis. The report suggests an overweight bias for NEO, citing the absence of resistance levels above the current price.
Form 8K NeoGenomics Inc For: 11 August By Investing.com
This article reports on NeoGenomics Inc.'s Form 8K filing for August 11th. The brief notice confirms the filing, and the article is primarily a placeholder for this regulatory update. No specific details about the content of the 8K filing are provided within this particular news item.
NeoGenomics announces planned departure of General Counsel Alicia Olivo
NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel, and Business Development, will depart from her role as General Counsel effective September 21, 2026, and will assist with the transition until October 2, 2026. This news follows the company's strong second-quarter 2026 earnings, which surpassed Wall Street expectations, leading Needham to raise its price target for NEO.
MFG Wealth Management Inc. Takes Position in NeoGenomics, Inc. $NEO
MFG Wealth Management Inc. has initiated a position in NeoGenomics, Inc. (NASDAQ:NEO) by purchasing 83,462 shares valued at approximately $1.22 million, representing about 0.06% of the company. Institutional investors and hedge funds collectively own 98.5% of NeoGenomics, which has received a "Moderate Buy" consensus rating from analysts with an average price target of $16.71. The medical research company recently exceeded quarterly expectations, reporting adjusted EPS of $0.05 and revenue of $201.66 million, an 11.2% increase year over year.
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics, Inc. has appointed Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of experience in commercial, product, and operations roles at data and technology companies, with significant expertise in AI and data insights in cancer care. Her appointment is expected to help NeoGenomics expand its portfolio and enhance its impact on cancer patients through innovative diagnostic solutions.
Neogenomics stock hits 52-week high at 16.46 USD
NeoGenomics Inc. (NEO) stock has reached a 52-week high of $16.46, driven by strong investor confidence and recent positive financial results. Despite being considered overvalued by InvestingPro analysis, the company's stock has delivered a 170% return over the past year, with analysts predicting profitability and upward earnings revisions. NeoGenomics also reported strong Q2 2026 earnings, exceeding expectations and leading to raised full-year guidance.
NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?
NeoGenomics (NEO) reported a return to quarterly profitability in Q2 2026 with revenue of US$201.66 million and a net income of US$2.24 million, a significant improvement from a net loss the previous year. Management also narrowed its expected full-year 2026 net loss and slightly raised its revenue outlook, signaling increased confidence in the business. This positive financial performance and updated guidance may reshape the investment narrative for NeoGenomics, particularly concerning its long-term path to sustained profitability and its fair value projections.
NeoGenomics, Inc. $NEO Stock Position Raised by Sei Investments Co.
Sei Investments Co. significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 320.7% during the first quarter, now holding 466,199 shares valued at $3.46 million. This move is mirrored by other institutional investors, collectively owning 98.5% of the company's stock, despite a recent insider share sale. Analysts maintain a "Moderate Buy" rating for NeoGenomics, with an average price target of $16.71, and the company recently surpassed quarterly earnings expectations.
Dimensional Fund Advisors LP Buys 225,588 Shares of NeoGenomics, Inc. $NEO
Dimensional Fund Advisors LP increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 9.2% in the first quarter, purchasing an additional 225,588 shares, bringing its total holdings to 2.67 million shares valued at approximately $19.8 million. This acquisition reflects a broader institutional interest in NeoGenomics, with several other large investors also adjusting their positions. The medical research company recently reported strong quarterly earnings, exceeding analyst expectations with an EPS of $0.05 and an 11.2% year-over-year revenue increase, while analysts maintain a "Moderate Buy" consensus rating for the stock.
How NeoGenomics’ Q2 Profit Return And Higher 2026 Outlook At NeoGenomics (NEO) Has Changed Its Investment Story
NeoGenomics (NEO) reported a return to profitability in Q2 2026 with US$2.24 million net income and raised its full-year 2026 revenue outlook to US$802 million–US$806 million, indicating improving operational performance. This positive shift strengthens the company's investment narrative, emphasizing its role as a specialized oncology testing player. However, valuation risks remain due to a relatively new management team and potential overvaluation of shares.
NeoGenomics, Inc. Revenue Breakdown – BX:NG9
NeoGenomics, Inc. (BX:NG9) generated 576.61 million CHF in revenue last year. The "Client Direct Billing" segment was the top performer, contributing 411.32 million CHF, a decrease from the previous year. The United States was the primary regional contributor, accounting for all of the company's revenue.
NeoGenomics Laboratories Number of Employees 2026 | Employee Count & Headcount Data
As of March 2026, NeoGenomics Laboratories, a Biotech and Healthcare Services company founded in 2002 and headquartered in Fort Myers, Florida, has approximately 2,124 total employees worldwide. This represents a 2.5% growth from 2023 but a 2.2% year-over-year decline in 2026. The company is actively hiring, with 121 active job postings in 2026, a 20.0% increase from 2025.
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
NeoGenomics, Inc. (NEO) recently hit a new 52-week high, with its stock up 4.5% in the past month and 34.7% since the start of the year. This outperformance is attributed to strong earnings surprises, with expected EPS growth of 50% for the current fiscal year and 95.83% for the next. While the stock trades at a premium valuation, its Zacks Rank of #2 (Buy) and strong Growth and Momentum Style Scores suggest potential for further gains.
NEO5107997 Bond Profile — Key Metrics
This article provides key metrics for the NEO5107997 bond issued by NeoGenomics, Inc. It details the bond's coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also includes a brief description of NeoGenomics, Inc., a clinical laboratory company specializing in cancer genetics diagnostic testing.
NEO Stock Price and Chart — NASDAQ:NEO
This article provides a comprehensive overview of NeoGenomics, Inc. (NASDAQ: NEO), including its stock price performance, key financial metrics, recent earnings report, and analyst ratings. It highlights the company's Q2 2026 revenue growth and increased full-year guidance. The article also includes various trading ideas and technical analyses from the community, alongside information on ETFs holding NEO stock.
BlackRock (NEO holder) discloses 20.4M-share NeoGenomics stake in latest update
BlackRock, Inc. has filed an amended beneficial ownership report revealing a 15.6% stake in NeoGenomics, Inc., totaling 20,358,331 shares. Of these, BlackRock holds sole voting power over 19,688,877 shares and sole dispositive power over all 20,358,331 shares. The filing also notes that the iShares Core S&P Small-Cap ETF has an interest exceeding five percent of NeoGenomics' outstanding common stock.
